The PROOF of Organ Failure Centre is a not-for-profit organization that develops and implements blood-based biomarker tests to better manage patients with heart, lung and kidney failure and prevent disease progression.
Health Briefs TV is a unique program featuring the best in the health and medical fields. It takes an inside look at the businesses and people who work to make life better for everyone. The show covers topics from alternative options in healthcare to innovative treatments for the prevention and management of the diseases affecting most people today.
Two BC researchers have combined forces to develop blood test that will identify patients at high risk for Chronic Obstructive Pulmonary Disease lung attacks. This much needed test will help medical professionals provide better treatment and ultimately lead to patients with fewer attacks, and reduced hospitalization and emergency visits.
Drs Don Sin and Raymond Ng hope to have the blood test ready to identify patients at high risk for attacks’, as well as be able to differentiate these attacks from other conditions. Ultimately, their goal is to ensure that patients who need preventative drugs will receive them, resulting in fewer attacks and significantly reducing the burden on the health care system. At the same time, patients at low risk of an attack will be able to avoid unnecessary drugs and their potential side effects.
The research project, entitled Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management is funded by Genome BC, Genome Canada, the PROOF Centre of Excellence , the St.
The PROOF Centre of Excellence team reflects on success in the context of work and life.
On any given day, you’ll find PROOF Centre staff and scientists scattered across the lower mainland, and busy working either at St. But on a recent and typically cloudy October afternoon, PROOF team members in Vancouver converged upon Cavino to mingle and reconnect.
With the team gathered togther, PROOF Centre’s CEO Dr. Bruce McManus , and COO Janet Wilson-McManus talked about the journey of taking a project, like the blood test for heart failure rejection, from concept to clinic, and they invited others to share their stories of success.
Breanne Crouch shared a story about stepping out of her own comfort zone of working in transplant research to working in a new arena of research, chronic obstructive pulmonary disease with a new population of patients. The program is underway with a successful start to patient enrollment.
Others in the PROOF team shared life successes, like relocating to a different country George Mak getting engaged to be married Shannon and becoming a tenured faculty
Success and failure are sometimes too goal-oriented,” reflected Dr. Instead of we should also think about The two terms are not identical sometimes having success does not mean satisfaction, and vice versa. Instead of we should also think about “regret”. Having failures does not mean that we have regret and sometimes people build their success on others’ regret. “Whether we’re talking about biomarkers or life, we start with a goal in mind. For Chen, success means being able to re-evaluate direction with each new learning, without being tied to the original intended goal. Gaby Cohen Freue says that the journey to success requires passion, patience and persistence to get through the bumpy patches. McManus used the analogy of President Abraham Lincoln, who was rejected time and again during his political career before eventually becoming one of the most-revered American presidents in history.
PROOF eyes success satisfaction, with no regrets as a team
With the heart failure program set to begin clinical validation, the COPD program in the midst of enrolling patients, and the announcement of a new collaboration to discover biomarkers of muscular dystrophy , it’s easy to forget that the road has been anything but smooth for the organization.
There’s something special about being here, particularly in the St. Paul’s environment,” observed Roxanne Rousseau, who spends most of her time at VGH.
Perhaps the secret that will carry PROOF through the coming months and years is the feeling of belonging to a team that cares.
The Council of Canadian Academies in collaboration with the Canadian Academy of Health Sciences recently released a new expert panel report, entitled The Health Effects of Conducted Energy Weapons . Bruce McManus was part of a 14-member panel of distinguished multidisciplinary experts chaired by the Honourable Justice Stephen T. Expert Panel was asked to consider the state of knowledge about the medical and physiological impacts of conducted energy weapons guns
PROOF Centre and MRM Proteomics Collaborate with the Jain Foundation to Identify Blood-Based Biomarkers of LGMD2B Muscular Dystrophy
Vancouver, BC and Seattle, WA 16, 2013 The Centre of Excellence for the Prevention of Organ Failure Centre and MRM Proteomics Inc. will use their biomarker expertise in collaboration with the Jain Foundation, Inc. to identify blood-based biomarkers of disease in individuals with a rare form of muscular dystrophy, called Limb?girdle muscular dystrophy 2B or Miyoshi Myopathy Since no effective treatment exists for LGMD2B MM, this study is an essential step towards developing therapies for patients living with these debilitating muscle diseases.
The Jain Foundation chose to collaborate with MRM Proteomics and the PROOF Centre because of their excellent track record of discovering molecular biomarkers in blood and developing them into tests that aid in the diagnosis and treatment of other diseases.
The Jain Foundation was impressed by the success PROOF Centre has had in moving biomarker programs from concept to the clinic, particularly with their recent clinical progress in finding a biomarker for rejection of a transplanted heart. Plavi MIttal, President and CEO, Jain Foundation
The study will compare blood samples from individuals with LGMD2B with samples from healthy, age and gender-matched controls. Differences in proteins and nucleic acids in the blood that reflect differences in muscle function will be tested and validated as possible biomarkers. These biomarkers will then be used to help track disease progression and the efficacy of potential treatments in future clinical trials.
About the Proof Centre of Excellence The Centre of Excellence for the Prevention of Organ Failure Centre develops blood tests to diagnose, treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, to improve heart, lung and kidney health and reduce the enormous socioeconomic burden of organ disease. The centre’s service arm provides expertise in computation, “-omic” science and biomarker workflow to organizations seeking to discover, develop and implement blood-based molecular biomarkers in a clinical setting. The PROOF Centre is a not-for-profit society initially established from the Networks of Centres of Excellence Secretariat under the Centre of Excellence for Commercialization and Research CECR Program, and is co-hosted by the University of British Columbia and Providence Health Care in Vancouver, British Columbia, Canada.
MRM Proteomics Inc. is a leader in providing advanced mass spectrometry based quantitative proteomics services and reagents to the pharmaceutical, biotechnology and diagnostics industries in key areas such as biomarker discovery and clinical diagnostics development.
The Jain Foundation is a non-profit organization with a mission to identify a cure or therapies for LGMD2B The foundation is privately funded and does not solicit funding from patients or other sources. The foundation’s activities include providing financial support to scientific researchers, identifying promising drug candidates, funding clinical trials and studies, educating patients and helping patients obtain genetic diagnoses.
Biomarkers market worth $40.8 billion by 2018
According to a recent report by market research and consulting firm MarketsandMarkets , the global Biomarkers Market is expected to grow at a CAGR of 18.5 from 2013 to 2018, to reach $40.8 billion by 2018.
A number of factors such as the rising demand for personalized medicine and companion diagnostics have increased the utility of Biomarkers in the healthcare sector.
Omics technology including, proteomics, genomics, transcriptomics, and metabolomics, is the largest segment contributing to the growth of this market.
The PROOF Centre of Excellence Partners With HTG Molecular Diagnostics to Begin Clinical Validation of Heart Transplant Rejection Blood Test
Vancouver, BC 25, 2013 Centre of Excellence for the Prevention of Organ Failure Centre and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients. The first clinical validation study of this kind in Canada, the blood test will allow doctors to better monitor and treat patients post-transplant.
HTG Molecular Diagnostics, a privately held, Tucson-based provider of molecular-technology solutions, will implement its proprietary HTG Edge System in the clinical laboratory of St. Paul’s Hospital, Providence Health Care, in Vancouver to begin validation studies of a molecular biomarker test developed by the PROOF Centre, a not-for-profit organization focused on developing blood tests for improved health.
Transplant patients are at greatest risk of organ rejection during the first three months post-surgery,” said Dr. Andy Ignaszewski, Head of Providence Health Care Division of Cardiology and Medical Director of the St.
The award-winning HTG Edge System is the only automated RNA analysis platform that delivers extraction-free, multiplexed results on a multitude of biological samples blood, serum, cells in 24 hours. The fully automated platform enables the analysis of as many as 47 different genes from minimal specimen volume with walk-away simplicity, eliminating the tedious extraction, amplification and labeling steps normally associated with RT-PCR.
The development of this blood test was driven by demand from patients who typically have to undergo at least 12 invasive biopsies per year in the first year post-transplant,” says Dr. “Currently, there is no globally accepted, affordable blood test available for monitoring heart transplant patients. The marriage of HTG Edge RNA analysis platform and PROOF Centre’s meticulous research will provide a testing mechanism to replace technology now available only at specialty laboratories.
While the blood test is being validated in the clinical laboratory setting, the PROOF Centre will also work with HTG Molecular Diagnostics to prepare for its regulatory approval in North America.
The clinical availability of HTG Molecular Diagnostics’ highly specific, extraction-free RNA analysis performed on blood will enable post-transplant monitoring with greater precision and turnaround time leading to superior patient management. In addition, avoiding invasive biopsies has the potential to improve patient outcomes” states Vijay Modur, M. HTG Molecular Diagnostics’ Vice President of Translational Science and Chief Medical Officer.
Funders of the clinical validation portion of the project include the PROOF Centre, Genome British Columbia, Provincial Health Services Authority, Providence Health Care Research Institute, Vancouver Coastal Health Research Institute, and the Transplant Research Foundation of BC.
About the Proof Centre of Excellence The Centre of Excellence for the Prevention of Organ Failure Centre develops blood tests to diagnose and better treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, focused on improving health and reducing the enormous socioeconomic burden of heart, lung and kidney disease. A not-for-profit society established in March 2008 by competitive funding from the Networks of Centres of Excellence Secretariat under the Centre of Excellence for Commercialization and Research CECR Program, the PROOF Centre is co-hosted by the University of British Columbia and Providence Health Care in Vancouver, British Columbia, Canada.
About HTG Molecular Diagnostics HTG Molecular Diagnostics is a privately held, Tucson-based company providing products for gene expression profiling, miRNA, and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. Additional information is available at http://www.htgmolecular.com .